NURIX THERAPEUTICS INC (NRIX)

US67080M1036 - Common Stock

23.82  +1.79 (+8.13%)

After market: 23.82 0 (0%)

News Image
a day ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment...

News Image
5 days ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted...

News Image
22 days ago - Investor's Business Daily

Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance

The Nasdaq and S&P 500 backed off highs. The Dow regained a key level.

News Image
22 days ago - USA News Group

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

News Image
22 days ago - USA News Group

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/PRNewswire/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of...

News Image
26 days ago - Investor's Business Daily

Biotech Stock Nurix Therapeutics Jumps On Positive Leukemia Treatment Trial

San Francisco-based Nurix Therapeutics reported robust results in an ongoing treatment against a stubborn form of leukemia.

News Image
26 days ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We have all of the biggest pre-market stock movers that investors are going to want to keep an eye on for Monday morning!

News Image
a month ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical...

News Image
a month ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

Webcast and call will be held at 9:00 a.m., ET (3:00 p.m., CEST), on Sunday, June 16, 2024, after the presentation at EHA2024...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Board Chair Transition

David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on...

News Image
2 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...

News Image
3 months ago - Market News Video

First Week of NRIX June 21st Options Trading

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Proposed Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...

News Image
3 months ago - InvestorPlace

NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024

NRIX stock results show that Nurix Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image
3 months ago - BusinessInsider

NRIX Stock Earnings: Nurix Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nurix Therapeutics (NASDAQ:NRIX) just reported results for the first quarter of...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix...

News Image
3 months ago - Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...